# Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy

Study · id `cardio:ct-nct06339411` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06339411](<https://clinicaltrials.gov/study/NCT06339411>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06339411

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06339411. Randomized; triple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06339411, source copy `cardio:ctgov-nct06339411-2026-08-11`, retrieved 2026-10-26)
- Planned start: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT06339411, source copy `cardio:ctgov-nct06339411-2026-08-11`, retrieved 2026-10-26)
- Primary completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT06339411, source copy `cardio:ctgov-nct06339411-2026-08-11`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT06339411, source copy `cardio:ctgov-nct06339411-2026-08-11`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06339411-2026-08-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy
- Acronym: CARE-EVT
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Cerebrolysin
- Intervention (Drug): Normal saline placebo
- Lead sponsor: Chang Gung Memorial Hospital
- Lead sponsor class: OTHER
- Collaborator: EVER Pharma France SAS
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Chang Gung Memorial Hospital (`cardio:org-chang-gung-memorial-hospital`)

## Provenance

Content hash: f5109981fe80e8707430b24f05a63fa760113a4a0ee5991d84250370e00fd7df
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
